Amneal Q1 revenue $659M (+18% YoY); GAAP net loss $92M on $94M opioid charge

Amneal Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.30 revenue$659,191,000

Net revenue $659M (+18% YoY); Generics +14%, Specialty +15%, AvKARE +33%.
GAAP net loss $92M ($0.30 loss per share) includes $94M pre-tax charge for nationwide opioids settlement in principle.
Adjusted EBITDA $152M (+31% YoY); adjusted diluted EPS $0.14 (vs $0.12 YoY).
Opioids settlement payable over ten years; company affirming 2024 full-year guidance.
All three segments posted double-digit revenue growth for first time in same quarter.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Amneal Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: revenue $659 million, net income $92 million, EPS $0.30. Guidance reaffirmed.

Period: the first quarter ended March 31, 2024
Revenue: $659 million
Net income: $92 million
EPS: $0.30
Guidance: reaffirmed
Result: reported results

Exact text from the filing

the information furnished pursuant to Item 2.02 of this report. --- EX-99.1 (EX-99.1) --- AMNEAL REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS ‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settlement in principle

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001723128-24-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.